ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)-RYWN

ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)-RYWN was reported 344 times

ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)-RYWN is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 CEREBRAL CANDIDIASIS 10 0.6667
1 GEMELLA BACTERAEMIA 1 0.5000
2 CHEMOTHERAPEUTIC DRUG LEVEL BELOW THERAPEUTIC 2 0.1333
3 CHEMOTHERAPEUTIC DRUG LEVEL DECREASED 1 0.0909
4 STOMATOCOCCAL INFECTION 9 0.0726
5 BASAL GANGLIA HAEMATOMA 2 0.0476
6 ENZYME ACTIVITY DECREASED 1 0.0455
7 RESPIRATORY MONILIASIS 10 0.0373
8 ASPERGILLUS TEST 1 0.0256
9 OPTIC NERVE SHEATH HAEMORRHAGE 2 0.0244
10 PARAINFLUENZA VIRUS INFECTION 2 0.0194
11 SKIN CANDIDA 10 0.0192
12 HYPERINSULINISM 2 0.0187
13 ANTITHROMBIN III DEFICIENCY 1 0.0112
14 ENZYME INHIBITION 1 0.0104
15 ENTEROBACTER TEST POSITIVE 2 0.0081
16 CULTURE WOUND POSITIVE 2 0.0077
17 LYMPHOID TISSUE HYPOPLASIA 1 0.0065
18 HYPERAMMONAEMIA 31 0.0062
19 SUBGALEAL HAEMATOMA 1 0.0060
20 THYMUS HYPOPLASIA 1 0.0057
21 HUMAN BOCAVIRUS INFECTION 1 0.0053
22 EYE INFECTION FUNGAL 2 0.0052
23 SUPERIOR SAGITTAL SINUS THROMBOSIS 4 0.0050
24 AMMONIA ABNORMAL 2 0.0050
25 T-CELL TYPE ACUTE LEUKAEMIA 1 0.0049
26 DRUG CLEARANCE INCREASED 1 0.0045
27 SYSTEMIC CANDIDA 11 0.0044
28 NOROVIRUS TEST POSITIVE 1 0.0031
29 ADMINISTRATION SITE SWELLING 1 0.0031
30 ESCHERICHIA BACTERAEMIA 7 0.0030
31 CYSTITIS BACTERIAL 1 0.0030
32 CEREBRAL MASS EFFECT 1 0.0028
33 ABSCESS BACTERIAL 1 0.0028
34 ANISOCORIA 1 0.0026
35 ADMINISTRATION SITE REACTION 1 0.0026
36 THERAPEUTIC PRODUCT EFFECT INCREASED 3 0.0026
37 SECONDARY IMMUNODEFICIENCY 3 0.0025
38 AMMONIA INCREASED 12 0.0023
39 MINIMAL RESIDUAL DISEASE 1 0.0021
40 SEPSIS SYNDROME 1 0.0020
41 INADEQUATE DIET 1 0.0019
42 PRODUCT CLOSURE ISSUE 1 0.0018
43 PANCREATITIS NECROTISING 4 0.0017
44 HYPERAMMONAEMIC ENCEPHALOPATHY 3 0.0017
45 HERPES SIMPLEX 11 0.0017
46 ESCHERICHIA TEST POSITIVE 2 0.0017
47 CEREBRAL ASPERGILLOSIS 1 0.0016
48 HEPATOBILIARY DISEASE 1 0.0016
49 VASOGENIC CEREBRAL OEDEMA 1 0.0014
50 MYCOBACTERIUM CHELONAE INFECTION 1 0.0014
51 CEREBRAL VENOUS SINUS THROMBOSIS 1 0.0012
52 ENTEROVIRUS INFECTION 1 0.0012
53 TREATMENT DELAYED 2 0.0012
54 PRODUCT USE IN UNAPPROVED THERAPEUTIC ENVIRONMENT 1 0.0011
55 PSEUDOMONAL SEPSIS 2 0.0011
56 HYPOFIBRINOGENAEMIA 1 0.0010
57 IMMEDIATE POST-INJECTION REACTION 1 0.0009
58 DIFFUSE ALVEOLAR DAMAGE 1 0.0009
59 NECROTISING FASCIITIS 3 0.0009
60 WHITE MATTER LESION 1 0.0008
61 PLATELET TRANSFUSION 1 0.0008
62 DRUG LEVEL BELOW THERAPEUTIC 4 0.0007
63 VIRAEMIA 1 0.0007
64 BLOOD CULTURE POSITIVE 2 0.0007
65 ANTIBODY TEST POSITIVE 1 0.0006
66 ENTEROBACTER INFECTION 1 0.0006
67 INJECTION SITE CELLULITIS 1 0.0005
68 HUMAN HERPESVIRUS 6 INFECTION 1 0.0005
69 BLOOD BICARBONATE DECREASED 1 0.0005
70 RHINOVIRUS INFECTION 2 0.0005
71 CYTOMEGALOVIRUS CHORIORETINITIS 1 0.0005
72 HYPERTRIGLYCERIDAEMIA 3 0.0005
73 FEBRILE NEUTROPENIA 28 0.0004
74 VENOOCCLUSIVE LIVER DISEASE 2 0.0004
75 VENOOCCLUSIVE DISEASE 1 0.0004
76 PANCREATITIS 20 0.0004
77 SUBDURAL HAEMORRHAGE 1 0.0004
78 RASH MORBILLIFORM 1 0.0004
79 CEREBRAL THROMBOSIS 1 0.0004
80 PNEUMATOSIS INTESTINALIS 1 0.0004
81 ENTEROCOLITIS 2 0.0003
82 PENILE PAIN 1 0.0003
83 INTRACARDIAC THROMBUS 1 0.0003
84 BRAIN DEATH 1 0.0003
85 INJECTION SITE HYPERSENSITIVITY 1 0.0003
86 CORONAVIRUS INFECTION 2 0.0003
87 ERYTHEMA NODOSUM 1 0.0003
88 RETINAL HAEMORRHAGE 2 0.0003
89 SKIN WEEPING 1 0.0003
90 AMYLASE INCREASED 1 0.0003
91 LEUKOENCEPHALOPATHY 1 0.0003
92 LIPASE INCREASED 2 0.0003
93 BRONCHOPULMONARY ASPERGILLOSIS 2 0.0003
94 HAEMORRHAGIC STROKE 2 0.0003
95 ANAPHYLACTIC REACTION 14 0.0003
96 BACTERAEMIA 3 0.0003
97 OESOPHAGEAL CANDIDIASIS 1 0.0003
98 GROIN PAIN 2 0.0002
99 CYTOMEGALOVIRUS VIRAEMIA 1 0.0002
100 LOCALISED OEDEMA 1 0.0002
101 INTERCEPTED MEDICATION ERROR 1 0.0002
102 DISSEMINATED INTRAVASCULAR COAGULATION 3 0.0002
103 SUBCUTANEOUS ABSCESS 1 0.0002
104 ENTEROCOCCAL INFECTION 1 0.0002
105 VITREOUS FLOATERS 2 0.0002
106 HYPERVOLAEMIA 1 0.0002
107 INJECTION SITE INFLAMMATION 1 0.0002
108 PARTIAL SEIZURES 1 0.0002
109 BLOOD TRIGLYCERIDES INCREASED 3 0.0002
110 TYPE 1 DIABETES MELLITUS 1 0.0002
111 BACTERIAL INFECTION 3 0.0002
112 ENTERITIS 1 0.0002
113 ASPERGILLUS INFECTION 1 0.0002
114 CARDIAC FAILURE ACUTE 1 0.0001
115 EYE HAEMORRHAGE 2 0.0001
116 GENERAL PHYSICAL CONDITION ABNORMAL 1 0.0001
117 INFARCTION 1 0.0001
118 CEREBRAL DISORDER 1 0.0001
119 ACIDOSIS 1 0.0001
120 PULMONARY HAEMORRHAGE 1 0.0001
121 PRODUCT ADMINISTRATION INTERRUPTED 1 0.0001
122 ESCHERICHIA INFECTION 1 0.0001
123 FACE OEDEMA 2 0.0001
124 CANDIDA INFECTION 2 0.0001
125 PRODUCT CONTAINER ISSUE 1 0.0001
126 MUCOSAL INFLAMMATION 3 0.0001
127 URTICARIA 19 0.0001
128 PRODUCT COMMUNICATION ISSUE 1 0.0001
129 HYPERSENSITIVITY 21 0.0001
130 RESPIRATORY RATE INCREASED 1 0.0001
131 MYOSITIS 1 0.0001
132 NEUTROPENIA 15 0.0001
133 LEUKAEMIA 1 0.0001
134 MULTIPLE ORGAN DYSFUNCTION SYNDROME 3 0.0001
135 POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME 1 0.0001
136 HYPOGLYCAEMIA 5 0.0001
137 TRANSFUSION 1 0.0001
138 CLOSTRIDIUM DIFFICILE COLITIS 1 0.0001
139 VIRAL INFECTION 3 0.0001
140 MALNUTRITION 1 0.0001
141 THERAPEUTIC PRODUCT EFFECT DECREASED 4 0.0001
142 LYMPHADENOPATHY 3 0.0001
143 CYTOPENIA 1 0.0001
144 ENCEPHALOPATHY 2 0.0001
145 INTERCEPTED PRODUCT PREPARATION ERROR 1 0.0001
146 ILEUS 1 0.0001
147 HAEMATEMESIS 2 0.0001
148 IMMUNE SYSTEM DISORDER 1 0.0001
149 MENTAL STATUS CHANGES 2 0.0001
150 HAEMORRHAGE INTRACRANIAL 1 0.0001
151 RASH ERYTHEMATOUS 3 0.0001
152 MANIA 1 0.0001
153 GENERALISED TONIC-CLONIC SEIZURE 1 0.0001
154 INCORRECT ROUTE OF PRODUCT ADMINISTRATION 1 0.0001
155 HAEMORRHAGE 6 0.0001
156 HYPERGLYCAEMIA 2 0.0001
157 SEPSIS 6 0.0001
158 HEPATIC STEATOSIS 1 0.0001
159 PANCYTOPENIA 3 0.0001
160 THROMBOCYTOPENIA 6 0.0001
161 ORAL HERPES 1 0.0001
162 FULL BLOOD COUNT DECREASED 1 0.0000
163 PRODUCT PREPARATION ERROR 1 0.0000
164 EATING DISORDER 1 0.0000
165 LIVER FUNCTION TEST INCREASED 1 0.0000
166 ALTERED STATE OF CONSCIOUSNESS 1 0.0000
167 INCORRECT PRODUCT ADMINISTRATION DURATION 1 0.0000
168 SEPTIC SHOCK 2 0.0000
169 RASH PAPULAR 1 0.0000
170 PANCREATITIS ACUTE 1 0.0000
171 RASH 18 0.0000
172 RESPIRATORY FAILURE 3 0.0000
173 CEREBRAL INFARCTION 1 0.0000
174 FLUSHING 4 0.0000
175 HYPOPHAGIA 1 0.0000
176 DRUG RESISTANCE 1 0.0000
177 OFF LABEL USE 33 0.0000
178 BLOOD BILIRUBIN INCREASED 1 0.0000
179 PALLOR 1 0.0000
180 CARDIAC ARREST 3 0.0000
181 RESPIRATORY DISTRESS 1 0.0000
182 VOMITING 17 0.0000
183 BLOOD CREATINE PHOSPHOKINASE INCREASED 1 0.0000
184 HEPATIC FAILURE 1 0.0000
185 STOMATITIS 2 0.0000
186 NAUSEA 26 0.0000
187 INJECTION SITE RASH 1 0.0000
188 ALANINE AMINOTRANSFERASE INCREASED 2 0.0000
189 DRUG INTOLERANCE 3 0.0000
190 STAPHYLOCOCCAL INFECTION 1 0.0000
191 INFUSION RELATED REACTION 2 0.0000
192 LIP SWELLING 1 0.0000
193 FUNGAL INFECTION 1 0.0000
194 URINARY RETENTION 1 0.0000
195 INJECTION SITE REACTION 2 0.0000
196 BURNING SENSATION 2 0.0000
197 PLATELET COUNT DECREASED 3 0.0000
198 ELECTROCARDIOGRAM QT PROLONGED 1 0.0000
199 UNDERDOSE 2 0.0000
200 AGITATION 2 0.0000
201 INJECTION SITE MASS 1 0.0000
202 HEPATIC FUNCTION ABNORMAL 1 0.0000
203 UNEVALUABLE EVENT 2 0.0000
204 PYREXIA 9 0.0000
205 SEIZURE 3 0.0000
206 DECREASED APPETITE 6 0.0000
207 CARDIAC FAILURE 2 0.0000
208 DYSKINESIA 1 0.0000
209 NEUTROPHIL COUNT DECREASED 1 0.0000
210 PRODUCT STORAGE ERROR 2 0.0000
211 DEHYDRATION 3 0.0000
212 VISION BLURRED 3 0.0000
213 INFECTION 3 0.0000
214 SYNCOPE 2 0.0000
215 CELLULITIS 1 0.0000
216 THERAPY CESSATION 1 0.0000
217 ILLNESS 2 0.0000
218 INFLAMMATION 1 0.0000
219 MUSCULOSKELETAL PAIN 1 0.0000
220 ASPARTATE AMINOTRANSFERASE INCREASED 1 0.0000
221 CONFUSIONAL STATE 3 0.0000
222 MEDICATION ERROR 1 0.0000
223 NECK PAIN 1 0.0000
224 OXYGEN SATURATION DECREASED 1 0.0000
225 EYE PAIN 1 0.0000
226 LETHARGY 1 0.0000
227 BONE PAIN 1 0.0000
228 PAIN IN EXTREMITY 5 0.0000
229 DISEASE PROGRESSION 2 0.0000
230 WHEEZING 1 0.0000
231 PLEURAL EFFUSION 1 0.0000
232 ANAEMIA 3 0.0000
233 HYPERHIDROSIS 2 0.0000
234 PRODUCT QUALITY ISSUE 2 0.0000
235 HEPATIC ENZYME INCREASED 1 0.0000
236 SKIN BURNING SENSATION 1 0.0000
237 MOBILITY DECREASED 1 0.0000
238 HALLUCINATION 1 0.0000
239 ACUTE KIDNEY INJURY 2 0.0000
240 INJECTION SITE PAIN 4 0.0000
241 HOSPITALISATION 2 0.0000
242 TOXICITY TO VARIOUS AGENTS 2 0.0000
243 CEREBROVASCULAR ACCIDENT 2 0.0000
244 MYALGIA 2 0.0000
245 TACHYCARDIA 1 0.0000
246 INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION 2 0.0000
247 COUGH 3 0.0000
248 PULMONARY EMBOLISM 1 0.0000
249 NEUROPATHY PERIPHERAL 1 0.0000
250 CONTUSION 1 0.0000
251 PRODUCT DOSE OMISSION ISSUE 3 0.0000
252 MALIGNANT NEOPLASM PROGRESSION 1 0.0000
253 HAEMOGLOBIN DECREASED 1 0.0000
254 ERYTHEMA 2 0.0000
255 HEADACHE 6 0.0000
256 HYPERTENSION 2 0.0000
257 PNEUMONIA 3 0.0000
258 FATIGUE 7 0.0000
259 MUSCULAR WEAKNESS 1 0.0000
260 INCORRECT DOSE ADMINISTERED 2 0.0000
261 ABDOMINAL PAIN 2 0.0000
262 INJECTION SITE ERYTHEMA 1 0.0000
263 PRURITUS 3 0.0000
264 DEATH 6 0.0000
265 BLOOD PRESSURE INCREASED 1 0.0000
266 DIARRHOEA 4 0.0000
267 TREMOR 1 0.0000
268 ABDOMINAL DISCOMFORT 1 0.0000
269 COVID-19 1 0.0000
270 CHEST PAIN 1 0.0000
271 ASTHENIA 2 0.0000
272 BLOOD GLUCOSE INCREASED 1 0.0000
273 DYSPNOEA 3 0.0000
274 GAIT DISTURBANCE 1 0.0000
275 HYPOTENSION 1 0.0000
276 SOMNOLENCE 1 0.0000
277 WRONG TECHNIQUE IN PRODUCT USAGE PROCESS 1 0.0000
278 ABDOMINAL PAIN UPPER 1 0.0000
279 ARTHRALGIA 2 0.0000
280 CONSTIPATION 1 0.0000
281 BACK PAIN 1 0.0000
282 PRODUCT USE IN UNAPPROVED INDICATION 1 0.0000
283 CONDITION AGGRAVATED 1 0.0000
284 PAIN 2 0.0000
285 MALAISE 1 0.0000
286 DRUG INEFFECTIVE 3 0.0000
287 DIZZINESS 1 0.0000